^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Galderma
Drug class:
Photosensitizer
Related drugs:
19d
Successful Treatment of MEK Inhibitor-Induced Paronychia in Neurofibromatosis with Photodynamic Therapy: A Case Report and Review of the Therapeutic Options. (PubMed, J Clin Med)
Background/Objectives: Selumetinib, a MEK1/2 inhibitor, is commonly used for treating neurofibromatosis type 1 (NF1) and is associated with cutaneous side effects such as paronychia and periungual granulomas...PDT was administered using methyl aminolevulinate (METVIX®) as the photosensitizing agent, followed by treatment with a red LED light source (630 nm, 37 J/cm2 for 8 min and 30 s)...This case demonstrates that PDT can provide a complete resolution of symptoms with a single treatment session, offering an alternative to more invasive procedures. Further studies with larger cohorts are needed to establish PDT as a standard treatment option for this condition.
Journal
|
NF1 (Neurofibromin 1)
|
Koselugo (selumetinib) • Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
1year
ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis (clinicaltrials.gov)
P=N/A, N=224, Completed, Galderma Laboratorium GmbH | Recruiting --> Completed | N=350 --> 224
Trial completion • Enrollment change
|
Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
over1year
New Treatments for Actinic Keratoses of the Scalp (clinicaltrials.gov)
P=N/A, N=120, Active, not recruiting, Helsinki University Central Hospital | Trial completion date: Jul 2024 --> Dec 2024
Trial completion date
|
Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
over1year
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study (clinicaltrials.gov)
P3, N=125, Terminated, Galderma R&D | Completed --> Terminated; The study was terminated early as per Sponsor's decision
Trial termination
|
Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
almost4years
MAL DL-PDT and Calcitriol for AK treatment of the upper extremities MAL DL-PDT e Calcitriolo per le AK degli arti superiori (clinicaltrialsregister.eu)
P3, N=36, Ongoing, ASL 1 AVEZZANO-SULMONA-L'AQUILA
Clinical • New P3 trial
|
CTGF (Connective tissue growth factor)
|
Metvixia (methyl aminolevulinate hydrochloride 16.8% cream)
Share via
